Impedimed (Australia) Performance

IPD Stock   0.02  0  5.56%   
The company retains a Market Volatility (i.e., Beta) of -1.62, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Impedimed are expected to decrease by larger amounts. On the other hand, during market turmoil, Impedimed is expected to outperform it. At this point, Impedimed has a negative expected return of -0.91%. Please make sure to check out Impedimed's value at risk, skewness, and the relationship between the maximum drawdown and potential upside , to decide if Impedimed performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Impedimed has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor
368:355
Last Split Date
2020-04-03
1
Is ImpediMed Limited stock testing key support - 2025 Historical Comparison AI Enhanced Trading Signals - Newser
12/01/2025
2
Is ImpediMed Limited stock testing key support - 2025 Earnings Impact Community Verified Swing Trade Signals - Newser
12/04/2025
3
Is ImpediMed Limited stock overpriced at current multiples - Profit Target Step-by-Step Swing Trade Plans - ulpravda.ru
01/08/2026
4
Bell Potter rates IPD as Speculative Buy - marketscreener.com
01/30/2026
5
IPD.AX ImpediMed Limited down 21.05 percent on 10 Feb 2026 heavy volume suggests watch for support - Meyka
02/09/2026
Begin Period Cash Flow24.6 M
Total Cashflows From Investing Activities-989 K
  

Impedimed Relative Risk vs. Return Landscape

If you would invest  3.60  in Impedimed on November 21, 2025 and sell it today you would lose (1.80) from holding Impedimed or give up 50.0% of portfolio value over 90 days. Impedimed is producing return of less than zero assuming 6.3344% volatility of returns over the 90 days investment horizon. Simply put, 56% of all stocks have less volatile historical return distribution than Impedimed, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days trading horizon Impedimed is expected to under-perform the market. In addition to that, the company is 8.49 times more volatile than its market benchmark. It trades about -0.14 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.15 per unit of volatility.

Impedimed Target Price Odds to finish over Current Price

The tendency of Impedimed Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.02 90 days 0.02 
about 98.0
Based on a normal probability distribution, the odds of Impedimed to move above the current price in 90 days from now is about 98.0 (This Impedimed probability density function shows the probability of Impedimed Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Impedimed has a beta of -1.62. This usually indicates as returns on its benchmark rise, returns on holding Impedimed are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Impedimed is expected to outperform its benchmark. Additionally Impedimed has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Impedimed Price Density   
       Price  

Predictive Modules for Impedimed

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Impedimed. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.026.35
Details
Intrinsic
Valuation
LowRealHigh
0.000.026.35
Details
Naive
Forecast
LowNextHigh
0.00040.026.36
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.003-0.0023-0.0014
Details

Impedimed Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Impedimed is not an exception. The market had few large corrections towards the Impedimed's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Impedimed, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Impedimed within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.82
β
Beta against Dow Jones-1.62
σ
Overall volatility
0.01
Ir
Information ratio -0.15

Impedimed Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Impedimed for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Impedimed can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Impedimed generated a negative expected return over the last 90 days
Impedimed has high historical volatility and very poor performance
Impedimed has some characteristics of a very speculative penny stock
Impedimed has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 12.72 M. Net Loss for the year was (23.24 M) with profit before overhead, payroll, taxes, and interest of 10.97 M.
Impedimed has accumulated about 21.68 M in cash with (14.64 M) of positive cash flow from operations.
Latest headline from news.google.com: IPD.AX ImpediMed Limited down 21.05 percent on 10 Feb 2026 heavy volume suggests watch for support - Meyka

Impedimed Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Impedimed Stock often depends not only on the future outlook of the current and potential Impedimed's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Impedimed's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares OutstandingB
Cash And Short Term Investments22.2 M

Impedimed Fundamentals Growth

Impedimed Stock prices reflect investors' perceptions of the future prospects and financial health of Impedimed, and Impedimed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Impedimed Stock performance.

About Impedimed Performance

Assessing Impedimed's fundamental ratios provides investors with valuable insights into Impedimed's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Impedimed is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Impedimed is entity of Australia. It is traded as Stock on AU exchange.

Things to note about Impedimed performance evaluation

Checking the ongoing alerts about Impedimed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Impedimed help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Impedimed generated a negative expected return over the last 90 days
Impedimed has high historical volatility and very poor performance
Impedimed has some characteristics of a very speculative penny stock
Impedimed has a very high chance of going through financial distress in the upcoming years
The company reported the revenue of 12.72 M. Net Loss for the year was (23.24 M) with profit before overhead, payroll, taxes, and interest of 10.97 M.
Impedimed has accumulated about 21.68 M in cash with (14.64 M) of positive cash flow from operations.
Latest headline from news.google.com: IPD.AX ImpediMed Limited down 21.05 percent on 10 Feb 2026 heavy volume suggests watch for support - Meyka
Evaluating Impedimed's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Impedimed's stock performance include:
  • Analyzing Impedimed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Impedimed's stock is overvalued or undervalued compared to its peers.
  • Examining Impedimed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Impedimed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Impedimed's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Impedimed's stock. These opinions can provide insight into Impedimed's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Impedimed's stock performance is not an exact science, and many factors can impact Impedimed's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Impedimed Stock Analysis

When running Impedimed's price analysis, check to measure Impedimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Impedimed is operating at the current time. Most of Impedimed's value examination focuses on studying past and present price action to predict the probability of Impedimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Impedimed's price. Additionally, you may evaluate how the addition of Impedimed to your portfolios can decrease your overall portfolio volatility.